Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Working Capital Changes (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Other Working Capital Changes data on record, last reported at -$109917.0 in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 140.3% year-over-year to -$109917.0; the TTM value through Dec 2025 reached -$813446.0, down 691.25%, while the annual FY2025 figure was -$429880.0, 2558.34% down from the prior year.
  • Other Working Capital Changes reached -$109917.0 in Q4 2025 per INM's latest filing, down from -$107412.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.2 million in Q1 2022 and bottomed at -$634410.0 in Q3 2021.
  • Average Other Working Capital Changes over 5 years is -$71145.3, with a median of -$109501.0 recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 62639.49% in 2023, down 1902.66% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$212964.0 in 2021, then skyrocketed by 100.22% to $471.0 in 2022, then soared by 62639.49% to $295503.0 in 2023, then fell by 7.7% to $272743.0 in 2024, then plummeted by 140.3% to -$109917.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$109917.0 in Q4 2025, -$107412.0 in Q3 2025, and -$114659.0 in Q2 2025.